ETFs & Funds
Home›ETFs & Funds›ETFs›Eli Lilly tailwind lifts active healthcare ETF GDOC
Eli Lilly tailwind lifts active healthcare ETF GDOC
GDOC is up 11.8% over the past three months, after JPMorgan raised its price target for its largest holding, Eli Lilly.
Healthcare and technology can behave differently in portfolios, and an ETF focused on active healthcare themes is seeing that contrast play out, according to ETF Trends.
ETF Trends reports that the Goldman Sachs Future Health Care Equity ETF, GDOC, received a boost from positive news tied to its largest holding, Eli Lilly. JPMorgan raised its price target for Eli Lilly this week, extending the fund’s strong run that has seen GDOC return 11.8% over the last three months, following earlier underperformance at the start of 2026.
The outlet also points to GDOC’s momentum improving, with the fund’s price rising above its 50-day simple moving average. GDOC charges a 75 basis point fee and uses an active, research-driven approach aimed at equities tied to global healthcare innovation, including areas such as genomics, precision medicine, and digital healthcare.
ETF Trends says the portfolio extends beyond Lilly, with Johnson and Johnson as the second-largest holding, returning nearly 30% year to date. It adds that Johnson and Johnson recently received FDA approval for a new cardiac catheter from its medical technology division. The ETF will also reach its fifth year of operation this fall, with the strategy using instruments such as futures, forwards, and options.